



Washington State Health Care Authority
Prescription Drug Program

P.O. Box 91132 • Seattle, Washington 98111-9232
206-521-2027 • FAX 206-521-2001 • TTY 360-923-2701 • www.rx.wa.gov

CORRECTED NOTICE RE: Changes to the Washington Preferred Drug List – ADHD Drugs

February 14, 2006

Dear Interested Party:

Following recommendations by the Washington State Pharmacy and Therapeutics Committee, the Department of Social and Health Services - Health and Recovery Services Administration (DSHS-HRSA), the Health Care Authority - Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List:

Attention Deficit/Hyperactivity Disorder

Short-Acting Products

methylphenidate HCL*
dexmethylphenidate HCl (Focalin®)
dextroamphetamine*

Intermediate-Acting Products

methylphenidate SA*
dextroamphetamine SA*

Long-Acting Products

dexmethylphenidate HCl (Focalin XR®)
methylphenidate LA (Metadate CD®;
Concerta®; Ritalin LA®)
amphetamine salt combination (Adderal XR®)

Non-Stimulant Product

atomoxetine (Strattera®)

*generic products only are preferred

Each agency will use the common PDL according to its benefit structure, including age and dosing limits.

DSHS-HRSA and UMP will implement the Attention Deficit/Hyperactivity Disorder class on April 1, 2006. The Department of Labor & Industries (L&I) will not be implementing this drug class as it is not part of the Workers' Compensation benefit.

If you have other questions or comments regarding this announcement, please contact Erika Clayton at (360) 923-2736 or by email at pdp@hca.wa.gov.

Sincerely,

Duane Thurman
Director, Prescription Drug Programs